Nitrumon
Nitrumon Brand names, Nitrumon Analogs
Nitrumon Brand Names Mixture
- No information avaliable
Nitrumon Chemical_Formula
C5H9Cl2N3O2
Nitrumon RX_link
http://www.rxlist.com/cgi/generic3/carmustine.htm
Nitrumon fda sheet
Nitrumon msds (material safety sheet)
Nitrumon Synthesis Reference
Johnston TP et al. J Med Chem 122:669-681(1963).
Nitrumon Molecular Weight
214.049 g/mol
Nitrumon Melting Point
31 oC
Nitrumon H2O Solubility
< 0.1 g/100 mL at 18 °C
Nitrumon State
Solid
Nitrumon LogP
1.256
Nitrumon Dosage Forms
Powder for solution; Wafer
Nitrumon Indication
For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.
Nitrumon Pharmacology
Carmustine is one of the nitrosoureas indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.
Nitrumon Absorption
5 to 28% bioavailability
Nitrumon side effects and Toxicity
The oral LD50s in rat and mouse are 20 mg/kg and 45 mg/kg, respectively. Side effects include leukopenia, thrombocytopenia, nausea. Toxic effects include pulmonary fibrosis (20-0%) and bone marrow toxicity.
Nitrumon Patient Information
No information avaliable
Nitrumon Organisms Affected
Humans and other mammals
